Knowledge Is Power for Today’s CEOs – Keeping Up With Industry News

Written by Igor Fisch, PhD on February 22, 2018

As a young scientist and entrepreneur, I understood early in my career just how important it is to stay ahead of the curve. Being a voracious consumer of information and news was the best way to see the big picture, evaluate trends and market drivers, and gain the knowledge that empowered my strategic vision. Today, […]

Read More

Using CHO “Omics” to Address Production of Increasingly Complex Biotherapeutics

Written by Guest Blogger Pierre-Alain Girod, PhD on February 1, 2018

Increasingly, solutions for complex human diseases are being addressed with increasingly complex protein therapeutic modalities. These include molecules such as bi-specific proteins, DARPins, triabodies and novel scaffolds decorated with peptides, enzymes or growth factors, to name a few. Many, if not most, of these proteins do not exist in nature and producing them presents a […]

Read More

2017: Year in Review

Written by Igor Fisch, PhD on January 4, 2018

An idea is something that won’t work unless you do. – Thomas Edison As I look around our new corporate headquarters and laboratories, I am reminded of how far Selexis has come since we began our work in cell line generation more than 15 years ago. 2017 was certainly no exception and I’m so proud […]

Read More

Biosimilarity: It starts by selecting the right manufacturing cell line

Written by Igor Fisch, PhD on December 21, 2017

The recombinant therapeutic patent cliff has ushered in a new promise for access to less expensive biologic therapies, called biosimilars. Just recently, in fact, the US Food & Drug Administration approved the first biosimilar for the treatment of certain breast and stomach cancers, known as Ogivri (trastuzumab-dkst) – which is a biosimilar to Herceptin (trastuzumab). […]

Read More

CHO Cells Are Here to Stay?

Written by Igor Fisch, PhD on November 30, 2017

I have recently read a couple of industry articles around cell line development that claim the Chinese hamster ovary (CHO) cell line is not the future of biomanufacturing and that alternative non-mammalian platforms, such as fungal, algae and plant systems, will offer the low-cost solutions that CHO cannot. Make no mistake, it will be a […]

Read More